The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
Adjuvant radiotherapy following radical prostatectomy (RP) for PCa with positive margins or extracapsular extension prolongs biochemical recurrence-free survival compared with RP alone, a study found.
Hypofractionated radiotherapy (HRT) offers quality-of-life outcomes similar to conventional radiation therapy for men with low-risk prostate cancer, according to recently published results of a phase 3 randomized study. HRT offers a less expensive and more convenient treatment option for some patients, and in light of the new findings about quality of life, should be considered…
In the phase 3 ARAMIS trial, darolutamide, a nonsteroidal androgen receptor inhibitor, significantly delayed development of metastasis in men with nonmetastatic castration-resistant prostate cancer.
Androgen deprivation therapy for prostate cancer is associated with a significant 20% increased risk of dementia and 14% increased risk of Alzheimer’s disease, a study found.